Swiss National Bank
CLSD

Swiss National Bank’s Clearside Biomedical CLSD Stock Holding History

Swiss National Bank’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,880
Closed -$224K – 2560
2017
Q1 		$224K Hold
1,880
– – ﹤0.01% 2511
2016
Q4 		$252K Buy
+1,880
New +$472K ﹤0.01% 2532

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Swiss National Bank's CLSD Position: Q2 2017 in Review

Swiss National Bank sold out of Clearside Biomedical (CLSD) in Q2 2017, closing a stake of 1,880 shares — an estimated $224K sold.

Swiss National Bank first reported a position in CLSD in Q4 2016 and held it in 2 quarters. The position peaked at $252K in Q4 2016. 53 funds tracked by Wall St. Rank hold CLSD as of Q2 2017.

  • Swiss National Bank reported no remaining Clearside Biomedical position as of Q2 2017 after selling out during the quarter.
  • Swiss National Bank sold 1,880 Clearside Biomedical shares in Q2 2017, an estimated $224K.
  • Swiss National Bank first reported a position in Clearside Biomedical in Q4 2016 and held it in 2 quarters.
  • Swiss National Bank's Clearside Biomedical position peaked at $252K in Q4 2016.
  • 53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2017.

Based on Swiss National Bank's 13F filing for Q2 2017, filed 9 Aug 2017.